Quest Diagnostics Incorporated (NYSE:DGX) reported Q2 2026 revenue of $3.04B (+10.2%), net income $320M and adj. EPS $3.12 (+19.1%), lifted guidance to $11.95–12.05B revenue and $11.05–11.25 adj. EPS, while UBS kept NYSE:DGX at Neutral, calling the stock fairly valued.
Previous Week Recap
- Quest Diagnostics Revenue, EPS Jump: Quest Diagnostics (DGX) Q2 2026: revenue $3.04B (+10.2%), net income $320M, diluted EPS $2.84, adj. EPS $3.12 (+19.1%). Reqs +13%, guidance raised: revenue $11.95–12.05B, adj. EPS $11.05–11.25.
- Quest Diagnostics Neutral Rating: UBS maintained Quest Diagnostics Incorporated (DGX) at a Neutral rating, stating the stock is viewed as fairly valued with limited upside or downside relative to its current price.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.